Interestingly, HSF1 was localized in the nucleus of CLL patients stratified as low risk (indolent disease or requiring no treatment, CLL#1) or high risk (relapsed/refractory disease or requiring treatment, CLL#2 and CLL#3) (Figure 1D). The gene discussed is HSF1; the disease is B-cell chronic lymphocytic leukemia.